u/Dionysaurus_Rex

Today’s Executive Order directing federal agencies to accelerate research and clarify regulatory pathways for psychedelic and related mental health therapies reflects growing recognition of the urgent need for new treatment options for serious mental health conditions. Increased federal attention to this area highlights both the scale of unmet need and the importance of advancing rigorously studied therapies through well-designed clinical trials and clear regulatory expectations.

At Helus Pharma, we believe meaningful progress depends on disciplined research, thoughtful clinical development, and the FDA’s established, science-based approval pathway. Collaboration across elected leaders, regulators, clinicians, and industry will be essential to advancing innovation responsibly and ensuring patients can benefit from safe, effective, and scalable new therapeutic options.